Posted by Michael Wonder on 29 Mar 2024
LISCure Biosciences receives US FDA fast track designation for LB-P8 for the treatment of primary sclerosing cholangitis
29 March 2024 - Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be in clinical development for the treatment of primary sclerosing cholangitis.
LISCure Biosciences announces the US FDA has granted fast track designation for LB-P8, LISCure's investigational drug for the treatment of primary sclerosing cholangitis.
